Chemoprevention of mammary cancer by diallyl selenide, a novel organoselenium compound

K. El-Bayoumy, Y. H. Chae, P. Upadhyaya, C. Ip

Research output: Contribution to journalArticle

53 Scopus citations

Abstract

Previous research has demonstrated that structurally distinctive organoselenium compounds are superior to the corresponding sulfur analogs in cancer prevention. The present study was designed to extend this observation to diallyl sulfide (DASe), a volatile synthetic compound, and diallyl sulfide (DAS), a flavor component of garlic. Their anticarcinogenic activities were evaluated using the 7,12-dimethylbenz(a)-anthracene (DMBA)-induced mammary tumor model. Rats were gavaged three times with DASe (6 or 12 μmol/kg body wt) or DAS (300, 900 or 1,800 μmol/kg) at 96, 48, and 24 hours before DMBA treatment. Significant tumor inhibition was found with the two doses of DASe and the highest dose of DAS. Based on these results, DASe appears to be at least 300 times more active than DAS. Analysis of total DMBA-DNA binding and individual DNA adducts in the mammary gland and liver showed that DASe had no effect on these parameters, suggesting that DASe might influence some unknown risk-associated events other than carcinogen activation/detoxification. Although the mechanism of action of DASe remains to elucidated, its potential relevance to natural products will be discussed in the context of the chemistry of selenium-enriched garlic which has been reported to be effective in cancer prevention in several studies.

Original languageEnglish (US)
Pages (from-to)2911-2915
Number of pages5
JournalAnticancer Research
Volume16
Issue number5 A
StatePublished - Sep 1 1996

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Chemoprevention of mammary cancer by diallyl selenide, a novel organoselenium compound'. Together they form a unique fingerprint.

  • Cite this